Paper33669809
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
Ventura F and 6 others. Biomedicines, 2021. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva. Papers, record 33669809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33669809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BFU2017-82421-P | Ministerio de Ciencia e Innovación | PubMed | ||
| 106169/ZZ14/Z | Wellcome | PubMed | ||
| STOPFOP grant number 821600 | FOP Friends and Innovative Medicines Initiative 2 Joint Undertaking | PubMed | ||
| 22379 | AFM-Telethon | PubMed | ||
| Grant Italia 2020 | FOP Italia | PubMed | ||
| 202038 | Fundacio la Marato de TV3 | PubMed | ||
| PHAEDRA-IMPACT | Netherlands Cardiovascular Research Initiative the Dutch Heart Foundation | PubMed |
Source PubMed
References171
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23412444 | Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. | Eur J Orthop Surg Traumatol | 2013 | https://conductscience.org/library/papers/23412444 | PubMed |
| 2 | 26721400 | Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/26721400 | PubMed |
| 3 | 27027798 | Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. | J Bone Miner Res | 2016 | https://conductscience.org/library/papers/27027798 | PubMed |
| 4 | 19243289 | TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. | Future Oncol | 2009 | https://conductscience.org/library/papers/19243289 | PubMed |
| 5 | 8242742 | Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. | Cell | 1993 | https://conductscience.org/library/papers/8242742 | PubMed |
| 6 | 22949078 | Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification. | Stem Cells | 2012 | https://conductscience.org/library/papers/22949078 | PubMed |
| 7 | 20463014 | Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20463014 | PubMed |
| 8 | 28754575 | Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva. | Bone | 2018 | https://conductscience.org/library/papers/28754575 | PubMed |
| 9 | 26493492 | Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. | Prostate | 2016 | https://conductscience.org/library/papers/26493492 | PubMed |
| 10 | 16753021 | Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). | J Bone Miner Res | 2006 | https://conductscience.org/library/papers/16753021 | PubMed |
| 11 | 26585533 | Pioneering government-sponsored drug repositioning collaborations: progress and learning. | Nat Rev Drug Discov | 2015 | https://conductscience.org/library/papers/26585533 | PubMed |
| 12 | 32304852 | Recent advances in the molecular mechanism of thalidomide teratogenicity. | Biomed Pharmacother | 2020 | https://conductscience.org/library/papers/32304852 | PubMed |
| 13 | 21460849 | Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. | Nat Med | 2011 | https://conductscience.org/library/papers/21460849 | PubMed |
| 14 | 21102460 | Conversion of vascular endothelial cells into multipotent stem-like cells. | Nat Med | 2010 | https://conductscience.org/library/papers/21102460 | PubMed |
| 15 | 29097342 | Variable signaling activity by FOP ACVR1 mutations. | Bone | 2018 | https://conductscience.org/library/papers/29097342 | PubMed |
| 16 | 32515349 | Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop. | Elife | 2020 | https://conductscience.org/library/papers/32515349 | PubMed |
| 17 | 24500035 | iPS cells: a game changer for future medicine. | EMBO J | 2014 | https://conductscience.org/library/papers/24500035 | PubMed |
| 18 | 27530160 | The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. | Stem Cell Res Ther | 2016 | https://conductscience.org/library/papers/27530160 | PubMed |
| 19 | 21791431 | The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor. | Blood | 2011 | https://conductscience.org/library/papers/21791431 | PubMed |
| 20 | 24691995 | SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. | Cancer Res | 2014 | https://conductscience.org/library/papers/24691995 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41017808 | A Narrative Review of Phase II and III Clinical Trials for the Pharmacological Treatment of Fibrodysplasia Ossificans Progressiva (FOP): Efficacy, Safety, and Challenges in Treatment Strategies. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41017808 | PubMed |
| 40416557 | Combined rapamycin and mesenchymal stem/stromal cells derived from induced pluripotent stem cells-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. | JBMR Plus | 2025 | https://conductscience.org/library/papers/40416557 | PubMed |
| 40274382 | Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva. | J Zhejiang Univ Sci B | 2025 | https://conductscience.org/library/papers/40274382 | PubMed |
| 40121219 | Interplay between ALK2R206H mutant receptor and autophagy signaling regulates receptor stability and its chondrogenic functions. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40121219 | PubMed |
| 38500216 | iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. | Stem Cell Res Ther | 2024 | https://conductscience.org/library/papers/38500216 | PubMed |
| 38254701 | How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. | Biomolecules | 2024 | https://conductscience.org/library/papers/38254701 | PubMed |
| 38136984 | Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. | Genes (Basel) | 2023 | https://conductscience.org/library/papers/38136984 | PubMed |
| 37521595 | Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. | Cureus | 2023 | https://conductscience.org/library/papers/37521595 | PubMed |
| 36522666 | The role of miRNA and lncRNA in heterotopic ossification pathogenesis. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/36522666 | PubMed |
| 35637634 | Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification. | J Bone Miner Res | 2022 | https://conductscience.org/library/papers/35637634 | PubMed |
| 35052819 | Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches". | Biomedicines | 2022 | https://conductscience.org/library/papers/35052819 | PubMed |
| 34440363 | Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis. | Genes (Basel) | 2021 | https://conductscience.org/library/papers/34440363 | PubMed |
Genes46
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33669809
GET https://conductscience.org/api/papers/v1/33669809/references?page=2